TY - JOUR T1 - Influenza vaccination in children with high-risk chronic diseases JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA3146 VL - 58 IS - suppl 65 SP - PA3146 AU - Elpis Hatziagorou AU - Evangelia Argyropoulou AU - Alexandra Soldatou AU - John Tsanakas Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA3146.abstract N2 - Objectives: To assess the seasonal Influenza vaccination coverage level for the 2020-2021 season (SARS-CoV-2 pandemic) in a population of CF patients and asthma compared to routine vaccination coverage.Method: The study included CF and asthma patients over six months of age, seen in a specialized CF and Asthma clinic in Northern Greece. The families were asked to fill in a questionnaire and send their vaccination charts status by e-mails to assess mandatory and recommended vaccine data. Telephone interviews were performed as well to assess possible factors associated with nonadherence with vaccination.Results: The study included 63 patients with CF (54% boys), mean age 14.29 years, and 41 patients with asthma (56.1% boys), mean age 12.34 years. Coverage for seasonal flu vaccination was 93,75% for CF and 58,54% for asthma patients  respectively (p<0.05). Coverage for polysaccharide pneumococcal vaccine was 73,44% for CF patients. Coverage for DTPCaHi, conjugate pneumococcal, MMR, and hepatitis B was 100% in 63.5%, 75-99% in 27%, and under 75% in 9.5% of the CF patients, respectively. Asthma patients showed 100% coverage for DTPCaHi, conjugate pneumococcal, MMR, and hepatitis B. The 96,83% of the CF and 92,68% of asthma parents reported that the clinicians informed them of their children’s routine and specific disease vaccination recommendations.Conclusion: Despite the physicians’ vaccination counseling, there was a significant difference in the seasonal flu vaccine coverage between CF and asthma patients. Influenza vaccination coverage depends mainly on the type of chronic disease. Further studies are needed to understand motivators and barriers to vaccination of children with chronic respiratory disease.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3146.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -